



Research on Clinical Treatment of Mesothelioma

Guest Editors:

Dr. Giulia M. Stella

1. Department of Internal
Medicine and Medical
Therapeutics, University of Pavia
Medical School, 27100 Pavia, Italy
2. Unit of Respiratory System
Diseases, Cardio-Thoracic and
Vascular Department, IRCCS
Fondazione Policlinico San
Matteo, 27100 Pavia, Italy

Dr. Walid Hadid

Interventional Pulmonary
Section, Community Health
Network, Heart and Vascular
Hospital, Community MD
Anderson Cancer Center North,
Indianapolis, IN, USA

Deadline for manuscript
submissions:

10 January 2025

Message from the Guest Editors

Dear Colleagues,

Pleural mesothelioma (PM) is a rare and aggressive neoplasm that originates from the pleural mesothelium and whose onset is mainly linked to occupational and/or environmental exposure to asbestos. Conventional chemotherapy as well as targeted therapies have failed against disease progression and patients' prognoses are still poor; in some instances, supportive care is the only therapeutic option. However, the advent of immunotherapy, the development of advanced cell therapy platforms, and the application of innovative technologies in cancer management have allowed some effective improvement in PM as well.

Thus, the aim of the present Special Issue is to recapitulate the current standard of care for this orphan cancer and to focus on novel and more promising approaches in PM screening, diagnosis, and treatment.

Dr. Giulia M. Stella

Dr. Walid Hadid

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)